AAPS: FDA/CDC ‘handle’ thimerosal link to neurodevelopmetal disorders

[SaneVax: The Association of American Physicians and Surgeons Inc. has revealed excerpts from the first meeting of the Advisory Committee on Immunization Practices (ACIP). This was a private meeting of select FDA/CDC officials and vaccine manufacturers held to discuss the potential link between thimerosal and neurodevelopmental disorders. Once you read the following article, you will know why it took a Freedom of Information Request to get transcripts of this meeting released to the public. Thanks to K.P. Stoller, M.D. for providing the information and comments.]

Selected vaccine authorities from CDC, FDA, and manufacturers discuss, in a closed meeting, the possibility of neurodevelopment disorders resulting from vaccine components.

Emphasis and comments in square brackets added by K.P. Stoller, M.D.

FDA/CDC and Pharma: AAPS reveals the truth

[The CDC published a study in late 2003, repudiating any possible link between thimerosal and developmental problems such as autism, but the CDC did have data supporting such a link which it secretively kept from the public.

Documents released through the Freedom of Information Act detail the transcript of a meeting held in June of 2000 between members of the CDC, the FDA, and representatives from the vaccine industry.

This top secret meeting was held to discuss a study done by Dr. Thomas Verstraeten and his co-workers using Vaccine Safety Datalink data as a project collaboration between the CDC’s National Immunization Program (NIP) and four HMOs. The study examined the records of 110,000 children.

The transcript is titled “Scientific Review of Vaccine Safety Datalink Information,” June 7-8, 2000, Simpsonwood Retreat Center, Norcross, Georgia, but it was also the first official meeting of the ACIP (Advisory Committee on Immunization Practices which sets CDC policy) work group on thimerosal and immunization. In attendance were Walter Orenstein, Director of the National Immunization Program (NIP) at the CDC; John Modlin, Chair of the ACIP and on the faculty at Dartmouth Medical School; and 50 other distinguished members of the government (11 consultants from the CDC), academia and the pharmaceutical industry. Vaccine industry representatives were: Harry Guess, M.D., Merck, Chief of Epidemiology; Jo White, M.D., North American Vaccine, Clinical Dev. & Research; Barbara Howe, M.D., Smith, Kline-Beecham, Clinical Research Group; Mike Blum, M.D., Wyeth, Safety and Surveillance for Vaccine Development.

Although this conference is apparently concerned with the effects of mercury in the form of thimerosal on infant brain development, participants seemed to have limited knowledge about mercury. None of the well known experts were invited, such as Dr. Ascher from Bowman Grey School of Medicine or Dr. Boyd Haley, who has done extensive work on the toxic effects of low concentrations on the CNS.

The conference followed a study that showed that mercury in vaccines may have caused neurodevelopment problems.

The following are in context excerpts of this 260 page transcript:]

Speak Your Mind

*

*